Axovant Sciences Ltd. said Tuesday a late-stage trial of a treatment for Alzheimer’s disease failed to meet its primary goals. The company said the phase 3 trial of intepirdine in patients with mild to moderate Alzheimer’s disease who were receiving donepezil therapy did not meet its primary endpoints. “At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition or in measures of activities of daily living as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and by the Alzheimer’s Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), respectively, compared to patients treated with placebo,” the company said in a statement. Alzheimer’s is the most common form of dementia and is fifth leading cause of death for people age 65 and older in the U.S. Axovant shares were halted premarket for the news, but have gained 95% in 2017, while the S&P 500 has gained 12%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News